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Abstract	  The	  pattern	  of	  recurrence	  after	  neoadjuvant	  chemoradiotherapy	  followed	  by	  transhiatal	   esophagectomy	  with	   limited	  mediastinal	   lymphadenectomy	   among	   73	  patients	   with	   carcinoma	   of	   the	   distal	   esophagus,	   gastroesophageal	   junction	   (GEJ)	  and/or	  gastric	  cardia,	  was	  investigated	  in	  this	  retrospective	  study.	  Results	  indicate	  that	   among	   the	   30	   patients	   with	   recurrence,	   distant	   sites	   (n	   =	   24)	   were	   more	  common	  than	  local	  sites	  (n	  =	  6)	  and	  this	  difference	  was	  statistically	  significant	  (P	  =	  0.001).	  Lungs	  and	  liver	  were	  the	  most	  common	  sites	  of	  first	  recurrence,	  51%,	  while	  mediastinal	  nodes	  were	  the	  sites	  of	  first	  recurrence	  in	  6%	  of	  cases.	  Twenty	  patients	  (27.4%)	   had	   pathologic	   complete	   response,	   20	   patients	   (27.4%)	   had	   disease	  downstaging,	   17	   patients	   (23.3%)	   had	   no	   response,	   and	   12	   (16.4%)	   had	   disease	  progression.	   Time	   to	   first	   recurrence	   was	   significantly	   reduced	   in	   patients	   with	  pathologic	   stage	   III	   disease	   (P	   =	   0.044).	   Patients	   receiving	   50	   Gy	   of	   neoadjuvant	  radiotherapy	   had	   lower	   rates	   of	   recurrence	   than	   patients	   receiving	   45	   Gy	   (P	   =	  0.025).	  Five-­‐year	  disease-­‐free	  survival	  and	  overall	  survival	  were	  61.6%	  and	  60.3%,	  respectively.	   Since	   mediastinal	   failure	   rates	   were	   significantly	   lower	   than	   distant	  failure	  rates	  in	  this	  study,	  it	  appears	  that	  aggressive	  mediastinal	  control	  at	  the	  time	  of	   esophagectomy	   in	   patients	  with	   carcinoma	  of	   the	   distal	   esophagus,	   GEJ	   and/or	  gastric	  cardia,	  who	  have	  received	  neoadjuvant	  chemoradiotherapy,	   is	  unnecessary.	  Furthermore,	   since	   pathologic	   stage	   of	   disease	   is	   significantly	   associated	   with	  disease	  recurrence,	  more	  efforts	  should	  be	  made	  to	  improve	  systemic	  therapy	  prior	  to	  and/or	  after	  resection.	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Introduction	  	   Esophageal	   cancer	   is	   the	   seventh	   leading	   cause	   of	   cancer	   death	   among	  American	  men	  and	  is	  the	  sixth	  leading	  cause	  of	  cancer	  death	  worldwide,	  responsible	  for	  286,000	  deaths	   (R.	  A.	  Malthaner,	   Collin,	  &	  Fenlon,	   2006).	  The	  National	  Cancer	  Institute	  estimates	  that	  in	  the	  United	  States	  16,640	  new	  cases	  arose	  in	  2010	  leading	  to	  14,500	  deaths	  ("Esophageal	  Cancer,"	  2010).	  The	  lifetime	  risk	  is	  0.8%	  for	  men	  and	  0.3%	  for	  women	  and	  the	  risk	  increases	  with	  age	  with	  mean	  age	  at	  diagnosis	  being	  67	   years.	   More	   than	   90%	   of	   esophageal	   cancers	   are	   either	   squamous	   cell	  carcinomas	   or	   adenocarcinomas	   while	   other	   carcinomas,	   including	   melanomas,	  leiomyosarcomas,	  carcinoids,	  and	   lymphomas	  are	   far	   less	  common.	  Approximately	  three	   quarters	   of	   adenocarcinomas	   are	   found	   in	   the	   distal	   esophagus	   whereas	  squamous	   cell	   carcinomas	   are	   more	   evenly	   distributed	   between	   the	   middle	   and	  lower	   thirds,	   while	   cancers	   of	   the	   cervical	   esophagus	   are	   uncommon.	   The	  demographics	   of	   esophageal	   cancer	   in	   the	  United	   States	   are	   changing	   as,	   in	  1975,	  squamous	   cell	   carcinoma	   accounted	   for	   75%	   of	   esophageal	   cancer	   while	  adenocarcinoma	  accounted	  for	  25%	  while,	  over	  the	  past	  20	  years,	  the	  incidence	  of	  squamous	   cell	   carcinoma	  has	  decreased	  and	   the	   incidence	  of	   adenocarcinoma	  has	  increased	   by	   up	   to	   450%	   in	   white	   men	   and	   50%	   among	   black	   men	   (Enzinger	   &	  Mayer,	   2003;	   R.	   A.	   Malthaner,	   et	   al.,	   2006).	   The	   pathogenesis	   of	   esophageal	  carcinoma	  remains	  unclear	  but	  animal	  studies	  suggest	  that	  “oxidative	  damage,	  from	  factors	   such	   as	   smoking	   and	   gastroesophageal	   reflux,	  which	   causes	   inflammation,	  esophagitis,	   and	   increased	   cell	   turnover,	   may	   initiate	   the	   carcinogenic	   process”	  (Enzinger	  &	  Mayer,	  2003).	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Despite	   its	   relatively	   low	   incidence,	   esophageal	   cancer	   is	   a	   deadly	   disease	  with	  more	   than	   50%	  of	   patients	   having	   unresectable	   or	  metastatic	   disease	   at	   the	  time	  of	  diagnosis.	  In	  fact,	  14%	  to	  21%	  of	  submucosal	  cancers	  (T1	  lesions)	  and	  38%	  to	  60%	  of	  cancers	  invading	  the	  muscularis	  propria	  (T2	  lesions)	  are	  associated	  with	  spread	   to	   lymph	   nodes,	   which	   is	   a	   poor	   prognostic	   indicator.	   Other	   independent	  indicators	   of	   poor	   prognosis	   are	   the	   tumor-­‐node-­‐metastasis	   (TNM)	   stage,	   weight	  loss	  of	  greater	  than	  10%	  of	  body	  mass,	  dysphagia,	  large	  tumors,	  and	  advanced	  age.	  The	  overall	  survival	  rate	  is	  poor	  but	  has	  increased	  from	  4%	  in	  the	  1970s	  to	  14%	  in	  2003	   (Enzinger	   &	   Mayer,	   2003).	   Stage	   IV	   disease	   is	   treated	   with	   palliative	  chemotherapy,	   however,	   it	   is	   controversial	   as	   to	   whether	   the	   optimal	   treatment	  strategy	   for	   patients	   with	   low	   stage	   locally	   resectable	   disease	   should	   be	   surgery	  alone	  with	   extensive	   lymphadenectomy	   or	   using	   neoadjuvant	   chemoradiotherapy	  or	  chemotherapy	  followed	  by	  surgery	  with	  limited	  lymph	  node	  dissection.	  	  	  	   As	   previously	   mentioned,	   lymph	   node	   metastasis	   is	   a	   poor	   prognostic	  indicator	   in	   esophageal	   cancer.	   There	   is	   however	   significant	   controversy	   among	  surgeons	   as	   to	   the	   extent	   of	   lymphadenectomy	   to	   be	   performed	   during	  esophagectomy	  (Altorki,	  et	  al.,	  2008;	  Schipper,	  2009).	  The	  prevailing	  view	  contends	  that	  the	  disease	  is	  systemic	  at	  the	  time	  of	  diagnosis	  and	  that	  extensive	  lymph	  node	  dissection	  only	  adds	  to	  the	  postoperative	  morbidity	  and	  so	  lymph	  node	  dissection	  is	  limited	  to	  periesophageal	  and	  perigastric	  nodes	  only.	   	  The	  opposing	  view	  supports	  extensive	   lymph	   node	   dissection	   to	   enhance	   accuracy	   of	   staging,	   improve	   local	  disease	   control	   and	   possibly	   improve	   survival	   (Altorki,	   et	   al.,	   2008).	   Multiple	  authors	  have	  shown	  an	  improvement	  in	  overall	  survival	  (OS)	  when	  extensive	  lymph	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node	   dissection	   is	   performed,	  with	   greater	   than	   25	   lymph	  nodes	   in	   node-­‐positive	  cancer	   showing	   improvement	   in	   OS,	   and	   greater	   than	   40	   lymph	   nodes	   in	   node-­‐negative	  cancer	  (Altorki,	  et	  al.,	  2008;	  Lee,	  Port,	  Paul,	  Stiles,	  &	  Altorki,	  2009;	  Peyre,	  et	  al.,	   2008;	   Schipper,	   2009;	   Stiles,	   et	   al.,	   2009).	   Other	   authors	   have	   demonstrated	  increased	   incidence	   of	   tracheobronchial	   lesions	   including	   fistulae,	   ulcers,	   and	  erosions	  that	  complicate	  esophagectomies	  with	  extensive	  lymphadenectomy	  of	  over	  60	   lymph	   nodes	   (Maruyama,	   et	   al.,	   2009;	   Schipper,	   2009).	   	   There	   is	   apparently	   a	  large	  gap	  between	  the	  number	  of	  nodes	  needed	  to	  achieve	  a	  survival	  benefit,	  and	  the	  number	  of	  nodes	  needed	   to	  be	   removed	   to	   increase	   the	   risk	  of	   tracheoesophageal	  lesions.	  However,	  Schipper	  pointed	  out	  that	  inconsistencies	  in	  the	  way	  lymph	  nodes	  are	   counted	   in	   different	   centers	   may	   account	   for	   this	   perceived	   gap	   (Schipper,	  2009).	  	  	  	   The	  two	  main	  techniques	  of	  surgical	  resection	  utilized	  for	  esophageal	  cancer	  are	   the	   transhiatal	   esophagectomy	   and	   the	   transthoracic	   esophagectomy.	   	   The	  transhiatal	  approach	  involves	  dissection	  of	  the	  esophagus	  under	  direct	  visualization	  through	   the	   widened	   hiatus	   of	   the	   diaphragm	   up	   to	   the	   pulmonary	   vein	   and	   the	  tumor	   is	   removed	   along	   with	   its	   adjacent	   lymph	   nodes	   (Hulscher,	   et	   al.,	   2002).	  Transthoracic	  en	  bloc	  resection	  involves	  a	  posterolateral	  thoracotomy	  and	  midline	  laparotomy	  along	  with	   extensive	   lymphadenectomy	  of	  mediastinal	   and	  abdominal	  nodes	   (two-­‐field	   dissection).	   In	   both	   procedures,	   the	   esophagogastrostomy	   is	  performed	  either	  in	  the	  chest	  (Ivor-­‐Lewis	  technique)	  or	  the	  neck	  (Enzinger	  &	  Mayer,	  2003;	  Hulscher,	   et	   al.,	   2002).	  The	   transthoracic	   en	  bloc	   resection	  may	  at	   times	  be	  accompanied	   by	   a	   three-­‐field	   dissection	   (3-­‐FL),	   which	   includes	   cervical	   node	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dissection	   along	   with	   mediastinal	   and	   abdominal	   nodes	   (Stiles,	   et	   al.,	   2009).	   In	  Japan,	   three-­‐field	  dissection	   is	   routinely	  performed	  because	   there	   is	  a	  high	  rate	  of	  cervical	  node	   involvement	   in	   this	  population.	  However,	  Law	  et	   al.	  discourages	   the	  practice	   of	   3-­‐FL	   as	   they	   have	   found	   that	   the	   rate	   of	   recurrence	   of	   cervical	   node	  involvement	   is	   uncommon	   and	   similar	   in	   both	   the	   three-­‐field	   and	   two-­‐field	  dissection	  groups	  and	  that	  there	  is	  no	  survival	  advantage	  (Law	  &	  Wong,	  2001).	  	  The	  authors	   also	   indicate	   that	   radical	   lymphadenectomy	   of	   the	   superior	  mediastinum	  may	   improve	   local	   disease	   control	   at	   the	   expense	   of	   increased	   postoperative	  morbidity	  and	  impaired	  quality-­‐of-­‐life	  (Law	  &	  Wong,	  2001).	  While	   the	   transhiatal	   and	   transthoracic	   surgical	   approaches	   to	   esophageal	  cancer	  are	  most	  commonly	  employed,	  minimally	  invasive	  esophagectomy	  is	  a	  newer	  technique	   used	   in	   a	   few	   centers	   worldwide.	   In	   1993,	   Collard	   and	   colleagues	  demonstrated	   that	   esophageal	   dissection	   could	   be	   carried	   out	   thoracoscopically,	  when	  combined	  with	  laparotomy	  for	  gastric	  mobilization.	  There	  have	  been	  multiple	  subsequent	   reports	  of	   esophagectomy	   for	   cancer,	   performed	  by	   thoracoscopy	  and	  open	  laparotomy,	  which	  have	  demonstrated	  the	  feasibility	  of	  thoracoscopic-­‐assisted	  esophagectomy,	   but	   the	   overall	   benefit	   was	   not	   well	   established.	   The	   current	  approach	  combines	  thoracoscopy	  and	  laparoscopy	  because	  laparoscopic	  esophageal	  mobilization	  by	  itself	  can	  be	  tedious	  and	  cumbersome	  via	  a	  completely	  laparoscopic	  approach	   and	   visualization	   of	   paraesophageal	   structures	   (such	   as	   the	   inferior	  pulmonary	   vein	   and	   the	   mainstem	   bronchi)	   and	   the	   performance	   of	   mediastinal	  lymph	   node	   dissection	   can	   be	   very	   limited	   (Schuchert,	   Luketich,	   &	   Landreneau).	  Pennathur	  and	  colleagues	  reported	  a	  series	  of	  222	  consecutive	  minimally	   invasive	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esophagectomies	   (MIE)	   in	   which	   minimally	   invasive	   esophagectomy	   was	  successfully	  completed	  in	  206	  (92.8%)	  patients.	  The	  median	  intensive	  care	  unit	  stay	  was	  1	  day,	  and	  the	  hospital	  stay	  was	  7	  days.	  The	  operative	  mortality	  was	  1.4%.	  The	  oncologic	  results,	  per	  stage,	  were	  similar	  to	  historic	  series	  of	  open	  esophagectomy	  (Pennathur,	  Zhang,	  Chen,	  &	  Luketich).	  	  Hulscher	   et	   al.	   compared	   survival	   outcomes	   of	   patients	   with	   resectable	  adenocarcinoma	   of	   the	  mid-­‐to-­‐distal	   esophagus	   or	   adenocarcinoma	   of	   the	   gastric	  cardia	   involving	   the	   distal	   esophagus	   according	   to	   whether	   they	   underwent	  transhiatal	  esophagectomy	  or	   transthoracic	  esophagectomy	  with	  extended	  en	  bloc	  lymphadenectomy	   (Hulscher,	   et	   al.,	   2002).	   The	   authors	   found	   a	   higher	   rate	   of	  perioperative	   morbidity	   among	   patients	   who	   underwent	   transthoracic	  esophagectomy	  although	  there	  was	  no	  significant	  difference	  in	  in-­‐hospital	  mortality	  (P=0.45).	  After	  a	  median	   follow-­‐up	  of	  4.7	  years,	  70%	  of	  patients	   in	   the	   transhiatal	  group	  had	  died	   compared	   to	  60%	  of	  patients	   in	   the	   transthoracic	  group	   (P=0.12).	  The	   disease-­‐free	   survival	   was	   27%	   for	   the	   transhiatal	   group	   versus	   39%	   for	   the	  transthoracic	   group,	  while	   the	   overall	   survival	  was	  29%	   for	   the	   transhiatal	   group	  versus	  39%	  for	  the	  transthoracic	  group.	  The	  differences	  in	  the	  median,	  disease-­‐free,	  and	   overall	   survival	   were	   not	   statistically	   significant,	   but	   the	   trend	   shows	   an	  improved	   long-­‐term	   survival	   at	   5	   years	   of	   the	   transthoracic	   approach	   over	  transhiatal	   approach	   (Hulscher,	   et	   al.,	   2002).	   The	   postoperative	   morbidity	  associated	   with	   extensive	   lymphadenectomy,	   however,	   leads	   other	   surgeons	   to	  consider	  alternative	  options.	  	  As	   an	   alternative	   to	   extensive	   lymphadenectomy	   at	   the	   time	   of	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esophagectomy,	  preoperative	  chemoradiation	  is	  becoming	  increasingly	  common	  in	  North	  America	  and	  Europe	  (Ku	  &	  Ilson,	  2009;	  Liu,	  Zhang,	  &	  Sun,	  2008;	  R.	  Malthaner	  &	  Fenlon,	  2001;	  Matsubara,	  2008;	  Urschel,	  Vasan,	  &	  Blewett,	  2002).	  In	  fact,	  Knisely	  et	  al.	   argue	   that	   the	  need	   for	  extensive	   lymphadenectomy	  may	  be	  obviated	  by	   the	  use	   of	   neoadjuvant	   chemoradiotherapy	   or	   chemotherapy	   and	   eliminate	   the	  associated	   perioperative	   morbidity	   (Knisely,	   Burtness,	   &	   Salem,	   2003).	   The	  theoretical	   advantages	   of	   neoadjuvant	   chemotherapy	   and/or	   chemoradiotherapy	  include	   improvement	   in	   baseline	   dysphagia,	   downgrading	   of	   primary	   tumor,	  increased	  resection	  rates,	  and	  the	  treatment	  of	  micrometastatic	  disease	  (Ku	  &	  Ilson,	  2009).	  In	  addition,	  patients	  with	  a	  complete	  pathologic	  response	  (pCR)	  typically	  fare	  better	   than	   patients	   who	   do	   not,	   but	   the	   pCR	   rate	   is	   2.5	   to	   5%	   of	   patients	   who	  receive	   neoadjuvant	   chemotherapy	   alone	   and	   in	   16%	   to	   51%	   of	   patients	   who	  receive	  neoadjuvant	  chemoradiation	  (Ku	  &	  Ilson,	  2009;	  Stiles,	  et	  al.,	  2009).	  	  Kleinberg	   et	   al	   assessed	   the	   long-­‐term	   survival	   results	   after	   cisplatin,	  protracted	   5-­‐fluorouracil	   infusion,	   and	   concurrent	   radiotherapy	   followed	   by	  surgical	  resection	  of	  esophageal	  cancer	  (Kleinberg,	  et	  al.,	  2003).	  The	  authors	  found	  a	  pathologic	  complete	  response	  (pCR)	  rate	  of	  33%	  among	  the	  study	  participants.	  The	  5-­‐year	   survival	   and	   disease-­‐free	   survival	   rates	   were	   40%	   and	   49%,	   respectively.	  Patients	  with	  a	  pCR	  had	  an	  overall	  5-­‐year	  survival	  rate	  of	  67%,	  while	  the	  remainder	  of	   patients	   had	   an	   overall	   survival	   rate	   of	   21%.	   These	   promising	   5-­‐year	   survival	  rates	   suggest	   that	   these	   intensive	   chemoradiotherapy	   regimens	  may	   improve	   the	  cure	   rate.	   Patients	   with	   Stage	   I	   tumors	   at	   the	   time	   of	   surgery	   had	   survival	   rates	  similar	   to	  patients	  with	  pCR,	  while	  patients	  with	  Stage	   IIA	  and	  higher	  disease	  had	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lower	   rates	   of	   median	   survival.	   This	   suggests	   that	   pathologic	   stage	   after	  neoadjuvant	   therapy	   is	  an	   important	  predictor	  of	  survival.	  The	  authors	  also	   found	  that	   isolated	   local	   recurrence	   is	   uncommon	   suggesting	   that	   efforts	   to	   improve	  neoadjuvant	   therapy	   should	   focus	   on	   improving	   systemic	   therapy	   rather	   than	  intensifying	  the	  radiation	  therapy	  (Kleinberg,	  et	  al.,	  2003).	  	  Furthermore,	   in	   2004,	   Malthaner	   et	   al	   published	   a	   systematic	   review	   and	  meta-­‐analysis	  pooling	  one-­‐year	  mortality	   from	  six	  randomized	  trials	  and	   found	  no	  statistically	   significant	   difference	   in	   mortality	   of	   neoadjuvant	   chemotherapy	   over	  surgery	  alone	  (R.	  A.	  Malthaner,	  Wong,	  Rumble,	  &	  Zuraw,	  2004b;	  Raja,	  Salhiyyah,	  &	  Nagarajan,	   2007).	   Based	   on	   this	   systematic	   review,	   subsequent	   external	   review,	  Practice	   Guidelines	   Coordinating	   Committee	   revision	   suggestions,	   and	   final	  approval,	   the	   Gastrointestinal	   Cancer	   Disease	   Site	   Group	   recommended	   that	   for	  adult	   patients	   with	   resectable	   thoracic	   esophageal	   cancer	   for	   whom	   surgery	   is	  considered	   appropriate,	   surgery	   alone	   be	   the	   standard	   of	   care	   (R.	   A.	   Malthaner,	  Wong,	  Rumble,	  &	  Zuraw,	  2004a;	  Raja,	  et	  al.,	  2007).	  Noting	  the	  conflicting	  results	  of	  several	   later	   studies	   investigating	  whether	   neoadjuvant	   chemotherapy	  provided	   a	  survival	  advantage	   for	  patients	  with	  resectable	  esophageal	  cancer,	  Malthaner	  et	  al	  later	  published	  a	  Cochrane	   systematic	   review	  of	  11	   randomized	   clinical	   trials	   and	  showed	  a	  trend	  toward	  benefit	  of	  neoadjuvant	  chemotherapy,	  although	  the	  benefit	  was	  not	  statistically	  significant	  (HR	  0.88,	  95%	  CI	  0.75	  –	  1.04)	  (R.	  A.	  Malthaner,	  et	  al.,	  2006).	  	  More	   recently,	   Gebski	   et	   al.	   published	   a	   meta-­‐analysis	   investigating	   the	  benefits	  of	  neoadjuvant	  chemoradiotherapy	  or	  chemotherapy	  versus	  surgery	  alone	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and	  determined	  that	  there	  is	  a	  significant	  survival	  benefit	  at	  2	  years	  for	  neoadjuvant	  chemoradiotherapy	   and,	   to	   a	   lesser	   extent,	   chemotherapy	   in	   patients	   with	  carcinoma	   of	   the	   esophagus	   (Gebski,	   et	   al.,	   2007).	   	   The	   authors	   found	   a	   relative	  reduction	   in	   all-­‐cause	   mortality	   for	   patients	   receiving	   neoadjuvant	  chemoradiotherapy	   versus	   surgery	   alone	   after	   pooling	   results	   from	   ten	   trials	  (hazard	  ratio	  0.81	  [95%	  CI	  0.70	  –	  0.93];	  p=0.002)	  corresponding	  to	  a	  13%	  absolute	  difference	  in	  survival	  at	  2	  years.	  	  Among	  eight	  reports	  comparing	  all-­‐cause	  mortality	  in	  patients	  treated	  with	  neoadjuvant	  chemotherapy	  versus	  surgery	  alone,	  there	  was	  a	   relative	   benefit	   in	   favor	   of	   chemotherapy,	  which	   just	   reached	   significance	   (0.90	  [0.81	  –	  1.00];	  p=0.05),	  corresponding	  to	  a	  7%	  absolute	  survival	  benefit	  at	  2	  years.	  The	   authors	   also	   assessed	   survival	   benefit	   of	   neoadjuvant	   therapies	   based	   on	  histological	   type	   of	   tumor.	   Patients	  with	   squamous	   cell	   carcinoma	   did	   not	   have	   a	  survival	   benefit	   from	   neoadjuvant	   chemotherapy	   (0.88	   [0.75-­‐1.03];	   p=0.12).	   One	  large	   study,	   the	   UK	   Medical	   Research	   Council	   (MRC)	   trial,	   showed	   a	   significant	  benefit	  to	  using	  neoadjuvant	  chemotherapy	  for	  patients	  with	  adenocarcinoma	  (0.78	  [0.64-­‐0.95];	   p=0.014),	   while	   another	   large	   study,	   the	   North	   American	   Intergroup	  113	   trial,	   using	   the	   same	   chemotherapy	   agents	   at	   higher	   doses	   did	   not	   show	   a	  benefit	   (Kelsen,	   et	   al.,	   1998;	   Ku	  &	   Ilson,	   2009;	   Surgical	   resection	  with	   or	  without	  preoperative	  chemotherapy	   in	  oesophageal	  cancer:	  a	   randomised	  controlled	   trial,"	  2002).	  Chemoradiotherapy	  was	  beneficial	  over	  surgery	  alone	  for	  both	  patients	  with	  squamous	   cell	   carcinoma	   (0.84	   [0.71-­‐0.99;	   p=0.04)	   and	   adenocarcinoma	   (0.75	  [0.59-­‐0.95];	  p=0.02).	  	  
	   13	  
Meguid	   et	   al,	   studied	   the	   pattern	   of	   recurrence	   among	   patients	   with	  esophageal	   cancer	   who	   had	   either	   a	   complete,	   partial,	   or	   no	   response	   to	  chemoradiotherapy	   before	   esophagectomy	   (Meguid,	   et	   al.,	   2009).	   	   The	   authors	  found	   that	   of	   267	   patients	   studied,	   30.7%	  had	   a	   complete	   response,	  while	   40.4%	  had	   partial	   response,	   and	   28.8%	   had	   no	   response.	   	   Of	   the	   patients	   who	   had	   a	  complete	  response,	  21.4%	  had	  recurrence	  of	  disease,	  while	  recurrence	  occurred	  in	  36.1%	   of	   patients	  with	   partial	   response	   and	   35.1%	   of	   patients	  with	   no	   response.	  Most	   recurrences	   occurred	   at	   distant	   sites	   (77.4%)	   regardless	   of	   pathologic	  response,	   and	   subsequent	   survival	  was	   brief	   (median	   8.37	  months).	   	   Disease-­‐free	  survival	  was	  longer	  for	  patients	  who	  had	  complete	  response	  to	  neoadjuvant	  therapy	  (median	   27.3	   months)	   compared	   to	   those	   who	   had	   a	   partial	   or	   no	   response	   to	  neoadjuvant	  therapy	  (median	  10	  months).	  	  Since	  it	  appears	  that	  it	  is	  the	  pathologic	  response	   of	   the	   tumor	   that	   determined	   recurrence	   rates	   in	   this	   population	   of	  patients,	  and	  most	  of	  the	  sites	  of	  first	  recurrence	  were	  distant	  from	  the	  location	  of	  the	   primary	   tumor,	   it	   is	   doubtful	   whether	   aggressive	   mediastinal	   control	   with	  lymphadenectomy	  at	  the	  time	  of	  esophagectomy	  is	  beneficial	  for	  patients	  who	  have	  had	  neoadjuvant	   chemoradiotherapy.	   	  As	  already	  mentioned,	   lymphadenectomy	   is	  associated	   with	   increased	   morbidity	   after	   surgery,	   which	   may	   affect	   patients’	  overall	   survival.	   	   Perhaps	   mediastinal	   control,	   if	   needed,	   may	   be	   achieved	   with	  neoadjuvant	  chemoradiotherapy.	  	  	  	  
	   14	  
Statement	  of	  Purpose	  The	   aim	  of	   the	   current	   study	   is	   to	   determine	   the	  patterns	   of	   recurrence	   of	  esophageal	   carcinoma	   after	   neoadjuvant	   chemoradiotherapy	   followed	   by	  transhiatal	   esophagectomy	   with	   minimal	   mediastinal	   lymph	   node	   dissection.	   We	  hypothesize	  that	  distant	  recurrence	  will	  be	  more	  common	  than	  local	  or	  mediastinal	  recurrence	  in	  patients	  who	  received	  trimodality	  therapy,	  thus	  obviating	  the	  need	  for	  aggressive	  mediastinal	  control	  with	  extensive	  lymph	  node	  dissection	  at	  the	  time	  of	  surgery.	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Materials	  and	  Methods	  
Study	  Population	  	   A	  database	  of	  150	  patients	  who	  underwent	  transhiatal	  esophagectomy	  at	  the	  Yale	   New	   Haven	   Hospital	   between	   September	   of	   1995	   and	   June	   of	   2009	   was	  searched	  to	  identify	  patients	  who	  underwent	  neoadjuvant	  chemoradiotherapy	  prior	  to	   transhiatal	   esophagectomy.	   Patients	   were	   included	   in	   the	   study	   if	   they	   were	  diagnosed	   with	   either	   adenocarcinoma	   or	   squamous	   cell	   carcinoma	   of	   the	   distal	  esophagus,	   gastroesophageal	   junction	   (GEJ),	   or	   the	   gastric	   cardia.	   Patients	   were	  excluded	  if	  they	  had	  tumor	  histology	  other	  than	  adenocarcinoma	  or	  squamous	  cell	  carcinoma.	   Patients	   who	   did	   not	   have	   neoadjuvant	   chemoradiotherapy	   prior	   to	  surgery	   were	   also	   excluded.	   After	   applying	   inclusion	   and	   exclusion	   criteria,	   73	  patients	   remained	   in	   the	   study.	   95%	   of	   patients	   in	   the	   study	   had	   complete	  preoperative	   clinical	   staging	   with	   endoscopic	   ultrasound	   (EUS).	   Staging	   was	  determined	  using	  the	  American	  Joint	  Commission	  (AJCC)	  2010	  TNM	  staging	  system.	  The	  study	  was	  approved	  by	  the	  Institutional	  Review	  Board	  (IRB)	  at	  the	  Yale	  School	  of	  Medicine.	  	  	  	  
Treatment	  
	   Neoadjuvant	  chemoradiotherapy	  varied	  by	  patient	  as	  some	  patients	  received	  medical	  and	  radiation	  oncology	   treatment	  at	  sites	  external	   to	   the	  Yale	  New	  Haven	  Hospital.	  However,	  for	  the	  majority	  of	  patients	  (n	  =	  54/73),	  chemotherapy	  consisted	  of	   5-­‐fluoropyrimidine	   (5-­‐FU),	   a	   platinum	   agent	   (either	   cisplatin	   or	   carboplatin),	  and/or	  a	  taxane	  (Table	  1).	  	  In	  addition,	  most	  patients	  had	  external	  beam	  radiation	  to	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the	  diseased	  portion	  of	  the	  esophagus	  to	  a	  dose	  between	  45	  Gy	  –	  50	  Gy	  (n	  =	  60/73;	  Table	   1).	   All	   patients	   underwent	   restaging	   EUS	   after	   neoadjuvant	  chemoradiotherapy	  and	  were	   taken	   to	   the	  operating	   room	  where	   they	  underwent	  transhiatal	   esophagectomy	   with	   limited	   lymph	   node	   dissection.	   In	   most	   cases,	  patients	   who	   had	   residual	   disease	   at	   the	   time	   of	   surgical	   resection	   were	   offered	  adjuvant	  therapy	  by	  their	  medical	  oncology	  providers.	  	  	  
Follow-­up	  and	  Recurrence	  	   Follow-­‐up	  time	  was	  calculated	  to	  be	  the	  number	  of	  months	  from	  the	  date	  of	  surgery	   to	   the	   date	   of	   last	   contact	   or	   death.	   The	   time	   to	   first	   recurrence	   was	  calculated	  to	  be	  the	  time	  from	  the	  date	  of	  surgery	  to	  the	  date	  of	  the	  first	  recurrence	  documented	  in	  the	  medical	  records.	  Follow-­‐up	  information	  was	  complete	  in	  60/73	  charts.	  	  
Statistical	  Analysis	  Data	   was	   collected	   in	   a	   retrospective	   manner	   and	   all	   analyses	   were	  performed	  using	  SPSS	  Analytical	  Software	  Package	  Version	  18.0	  (SPSS,	  Chicago,	  IL).	  The	  differences	  between	  groups	  were	  tested	  for	  significance	  by	  the	  Student	  t	  test	  for	  continuous	   variables	   and	   Fisher	   exact	   test	   or	   Pearson’s	   chi-­‐squared	   test	   for	  categorical	   variables.	   Binomial	   testing	   was	   used	   to	   determine	   the	   statistical	  difference	   between	   the	   groups	   of	   patients	   with	   local	   versus	   distant	   recurrence.	  Univariable	   Cox	   regression	   analyses	   were	   performed	   with	   disease	   recurrence	   or	  death	   as	   the	   outcomes	   with	   a	   significance	   level	   of	   P<0.05.	   Covariates	   that	   were	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significant	   at	   P	   <0.25	  were	   included	   in	   the	  multivariable	   Cox	   regression	   analyses.	  Kaplan-­‐Meier	   analysis	   was	   used	   to	   calculate	   disease	   recurrence	   functions	   and	  differences	  were	  assessed	  using	  the	  log-­‐rank	  test.	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Results	  
Patient	  Characteristics	  Patient	  demographics	  along	  with	  clinical	  and	  pathological	   characteristics	  of	  the	  tumors	  are	  presented	  in	  Table	  1.	  	  Of	  the	  73	  patients	  in	  the	  population,	  63	  were	  male	  and	  10	  were	  female.	  The	  mean	  age	  was	  58.63	  (SD	  9.082;	  range,	  27	  years	  –	  74	  years).	  	  The	  majority	  of	  the	  patients	  were	  Non-­‐Hispanic	  White,	  accounting	  for	  87.7%	  of	   the	   study	   population.	   8.2%	   of	   the	   population	  was	   Non-­‐Hispanic	   Black	   and	   the	  remaining	   4.1%	   were	   either	   Hispanic	   or	   other	   unspecified	   race.	   Forty-­‐seven	  patients	   had	   a	   history	   of	   alcohol	   use	   and	  63	  had	   a	   tobacco	  use	  history.	   Sixty-­‐four	  patients	   were	   diagnosed	   with	   adenocarcinoma,	   while	   9	   had	   squamous	   cell	  carcinoma.	   At	   the	   time	   of	   diagnosis,	   the	   majority	   of	   patients	   had	   stage	   II	   or	   III	  disease	  (n	  =	  63/73).	  After	  trimodality	  therapy,	  20	  patients	  (27.4%)	  had	  a	  complete	  response	  (CR)	  and	  were	  noted	  to	  have	  stage	  0	  disease	  at	  the	  time	  of	  surgery.	  Twenty	  patients	  (27.4%)	  had	  the	  stage	  of	  their	  disease	  lowered	  but	  had	  residual	  disease	  on	  surgical	   pathology.	   Seventeen	   patients	   (23.3%)	   had	   the	   same	   pathologic	   stage	   as	  clinical	   stage	   after	   trimodality	   therapy	   and	   12	   patients	   (15.4%)	   had	   disease	  upstaging	  after	   therapy.	   	   It	  was	  not	  possible	   to	  quantify	  response	   to	   therapy	   for	  4	  patients	   who	   either	   did	   not	   have	   a	   recorded	   clinical	   stage	   or	   pathological	   stage.	  After	   trimodality	   therapy,	   20	   patients	   (27.4%)	   had	   stage	   0	   disease,	   12	   patients	  (16.4%)	  had	   stage	   I	   disease,	   23	   patients	   (31.5%)	  had	   stage	   II	   disease,	   and	   only	   3	  patients	  (4.1%)	  had	  stage	  IV	  disease.	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Table	  1	  Patient	  Characteristics	  and	  Univariable	  Cox	  Regression	  Analysis	  for	  Disease-­Free	  Survival	  
Characteristic	   No.	  (std	  dev)	   %	   HR	   95%	  CI	   P	  
Gender	   	  	   	  	   	  	   	  	   	  	  Male	   63	   86.3	   1	   	  	   	  	  Female	   10	   13.7	   1.565	   0.358-­‐6.843	   0.552	  Age	   58.63	  (9.082)	   100.0	   0.989	   0.937-­‐1.044	   0.691	  
Race	   	  	   	  	   	  	   	  	   	  	  Non-­‐Hispanic	  White	   64	   87.7	   1	   	  	   	  	  Non-­‐Hispanic	  Black	   6	   8.2	   1.886	   0.430-­‐8.276	   0.400	  Other	   3	   4.1	   1.795	   0.233-­‐13.841	   0.575	  
Alcohol	  use	  history	   	  	   	  	   	  	   	  	   	  	  No	   25	   34.2	   1	   	  	   	  	  Yes	   47	   64.4	   0.963	   0.422-­‐2.199	   0.929	  Unknown	   1	   1.4	   	  	   	  	   	  	  
Tobacco	  Use	  history	   	  	   	  	   	  	   	  	   	  	  No	   9	   12.3	   1	   	  	   	  	  Yes	   63	   86.3	   0.913	   0.210-­‐3.968	   0.903	  Unknown	   1	   1.4	   	  	   	  	   	  	  
Histology	   	  	   	  	   	  	   	  	   	  	  Adenocarcinoma	   64	   87.7	   1	   	  	   	  	  Squamous	  Cell	  Carcinoma	   9	   12.3	   3.362	   0.704-­‐16.068	   0.129	  
Response	  to	  treatment	   	  	   	  	   	  	   	  	   	  	  No	  response	   17	   23.3	   1	   	  	   	  	  Downstaging	  without	  complete	  response	   20	   27.4	   0.986	   0.350-­‐2.781	   0.979	  Downstaging	  with	  complete	  response	   20	   27.4	   1.241	   0.382-­‐4.029	   0.719	  Disease	  progression	   12	   16.4	   1.544	   0.461-­‐5.172	   0.481	  Unknown	   4	   5.5	   	  	   	  	   	  	  
Clinical	  Stage	   	  	   	  	   	  	   	  	   	  	  Stage	  I	   5	   6.8	   1	   	  	   	  	  Stage	  II	   36	   49.3	   0.103	   0.009-­‐1.212	   0.071	  Stage	  III	   27	   37.0	   0.092	   0.008-­‐1.083	   0.058	  Stage	  IV	   1	   1.4	   0.208	   0.009-­‐4.614	   0.322	  unstaged	   4	   5.5	   	  	   	  	   	  	  
Pathologic	  Stage	  	   	  	   	  	   	  	   	  	   	  	  Stage	  0	   20	   27.4	   1	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Stage	  I	   12	   16.4	   0.489	   0.094-­‐2.539	   0.395	  Stage	  II	   23	   31.5	   0.469	   0.153-­‐1.440	   0.186	  Stage	  III	   14	   19.2	   2.442	   0.768-­‐7.770	   0.131	  Stage	  IV	   3	   4.1	   0.406	   0.046-­‐3.562	   0.416	  unstaged	   1	   1.4	   	  	   	  	   	  	  
Type	  of	  Neoadjuvant	  chemotherapy	  received	   	  	   	  	   	  	   	  	   	  	  Cisplatin/5-­‐FU	   39	   53.4	   1	   	  	   	  	  Cisplatin/5-­‐FU/Taxol	   9	   12.3	   0.949	   0.261-­‐3.445	   0.937	  Cisplatin/Taxol	   6	   8.2	   0.467	   0.149-­‐1.465	   0.192	  Other	   15	   20.5	   0.657	   0.254-­‐1.697	   0.386	  Unknown	   4	   5.5	   	  	   	  	   	  	  
Dose	  of	  external	  beam	  radiation	   	  	   	  	   	  	   	  	   	  	  45	  Gy	   43	   58.9	   1	   	  	   	  	  50	  Gy	   17	   23.3	   0.370	   0.150-­‐0.913	   0.031	  52	  Gy	  -­‐	  60	  Gy	   4	   5.5	   5.187	   1.031-­‐26.081	   0.046	  unknown	   7	   9.6	   	  	   	  	   	  	  None	   2	   2.7	   	  	   	  	   	  	  	  
Response	  to	  Treatment	  	   Seventeen	  patients	  (23.3%)	  in	  the	  study	  did	  not	  have	  a	  pathological	  response	  to	   trimodality	   therapy.	   Of	   the	   non-­‐responders,	   2	   patients	   (11.8%)	   had	   squamous	  cell	   carcinoma	   and	   15	   patients	   (88.2%)	   had	   adenocarcinoma.	   Twenty	   patients	  (29.0%)	  had	  a	  pathologic	   complete	   response	  and	  of	   these,	  4	  patients	   (20.0%)	  had	  squamous	   cell	   carcinoma	   compared	   to	   16	  patients	   (80.0%)	  with	   adenocarcinoma.	  Twenty	  patients	  (29.0%)	  had	  a	  lower	  stage	  of	  disease	  after	  trimodality	  therapy	  and	  of	  these,	  2	  patients	  (10.0%)	  had	  squamous	  cell	  carcinoma	  and	  18	  patients	  (90.0%)	  had	   adenocarcinoma.	   Only	   12	   patients	   (16.2%)	   had	   disease	   upstaging	   during	  therapy	  and	  of	  these,	  1	  patient	  (8.3%)	  had	  squamous	  cell	  carcinoma	  and	  11	  patients	  (91.7%)	   had	   adenocarcinoma	   (Table	   2).	   Of	   the	   patients	   with	   squamous	   cell	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carcinoma,	   4	   (44.4%)	   had	   a	   complete	   response	   to	   treatment	   and	   2	   (22.2%)	   had	  disease	   downstaging	   with	   treatment.	   Two	   patients	   (22.2%)	   with	   squamous	   cell	  carcinoma	   showed	  no	  pathologic	   response	   to	   therapy,	   and	  1	   (11.1%)	  had	  disease	  progression	   with	   therapy.	   The	   majority	   of	   patients	   with	   adenocarcinoma	   had	   a	  pathologic	  response	  to	  therapy,	  18	  (30.0%)	  downstaged	  without	  complete	  response	  while	   16	   (26.7%)	   downstaged	   with	   complete	   response.	   Fifteen	   patients	   (25.0%)	  with	  adenocarcinoma	  had	  the	  same	  pathological	  stage	  as	  clinical	  stage	  after	  therapy,	  and	   11	   (18.3%)	   had	   disease	   progression	   with	   therapy.	   Chi-­‐squared	   analysis	  revealed	   no	   significant	   difference	   between	   adenocarcinoma	   and	   squamous	   cell	  carcinoma	  in	  terms	  of	  their	  response	  to	  chemoradiotherapy	  (P	  =	  0.735).	  	  	  
Table	  2	  Response	  to	  trimodality	  therapy	  by	  carcinoma	  histology	  
Response	  to	  Treatment	   Squamous	  Cell	  Carcinoma	   Adenocarcinoma	   Total	  
No	  response	   2	  (22.2%)	   15	  (25.0%)	   17	  (24.6%)	  
Downstaged	  without	  complete	  response	   2	  (22.2%)	   18	  (30.0%)	   20	  (29.0%)	  
Downstaged	  with	  complete	  response	   4	  (44.4%)	   16	  (26.7%)	   20	  (29.0%)	  
Disease	  progression	   1	  (11.1%)	   11	  (18.3%)	   12	  (17.4%)	  
Total	   9	  (100%)	   60	  (100.0%)	   69	  (100.0%)	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Recurrence	  of	  Esophageal	  Carcinoma	  At	  our	  significance	  level	  of	  0.05,	  there	  is	  no	  evidence	  to	  suggest	  that	  there	  is	  a	  relationship	   between	   age,	   gender,	   tobacco	   use	   history,	   tumor	   histology,	   clinical	  stage,	   pathologic	   stage,	   or	   response	   to	   therapy,	   with	   recurrence	   of	   esophageal	  carcinoma	  after	  trimodality	  therapy	  (P	  >	  0.05;	  Table	  3).	  	  
Table	  3	  Statistical	  relationship	  between	  the	  independent	  variables	  and	  the	  incidence	  of	  recurrence	  





recurrence	   P	  
Age	   30	   43	   0.085	  
Gender	   	  	   	  	   0.144	  M	   28	   35	   	  	  F	   2	   8	   	  	  
Tobacco	  Use	  History	   	  	   	  	   0.238	  No	   2	   7	   	  	  Yes	   27	   36	   	  	  
Alcohol	  Use	  History	   	  	   	  	   0.589	  No	   9	   16	   	  	  Yes	   20	   27	   	  	  
Histology	   	  	   	  	   0.219	  Adenocarcinoma	   28	   36	   	  	  Squamous	  Cell	  Carcinoma	   2	   7	   	  	  
Clinical	  stage	   	  	   	  	   0.096	  I	   1	   4	   	  	  II	   11	   25	   	  	  III	   15	   12	   	  	  IV	   1	   0	   	  	  
Pathological	  Stage	   	  	   	  	   0.147	  0	   6	   14	   	  	  I	   2	   10	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II	   13	   10	   	  	  III	   7	   7	   	  	  IV	   1	   2	   	  	  
Response	  to	  Treatment	   	  	   	  	   0.789	  No	  response	   7	   10	   	  	  Downstaging	  without	  complete	  response	   9	   11	   	  	  Downstaging	  with	  complete	  response	   6	   14	   	  	  Disease	  progression	   5	   7	   	  	  
Type	  of	  Neoadjuvant	  
chemotherapy	  received	   	  	   	  	   0.550	  Cisplatin/5-­‐FU	   15	   24	   	  	  Cisplatin/5-­‐FU/Taxol	   3	   6	   	  	  Cisplatin/Taxol	   4	   2	   	  	  Other	   7	   8	   	  	  
Dose	  of	  external	  beam	  radiation	   	  	   	  	   0.904	  
45	  Gy	   18	   25	   	  	   	  	   	  50	  Gy	   8	   9	   	  	  52	  Gy	  -­‐	  60	  Gy	   2	   2	   	  	  	   The	  mean	   follow-­‐up	   time	  was	  40.90	  ±	   38.76	  months	   (range,	  0	  months-­‐153	  months).	   At	   the	   time	   of	   the	   last	   follow-­‐up,	   30	   patients	   (41.1%)	   had	   recurrent	  disease,	  while	  43	  patients	  (58.9%)	  remained	  disease-­‐free.	  The	  majority	  of	  patients	  with	  recurrence	  (n=24/30;	  80.0%),	  had	  disease	  distant	  from	  the	  site	  of	  origin	  of	  the	  tumor	  (Table	  4).	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Table	  4	  Patients	  with	  recurrent	  disease	  at	  last	  follow-­up	  
Recurrence	   No.	   %	  Yes	   30	   41.1	  No	   43	   58.9	  Local	   6	   20.0	  Distant	   24	   80.0	  	   Binomial	  testing	  further	  revealed	  that	  the	  difference	  between	  the	  number	  of	  patients	   with	   local	   recurrence	   and	   those	   with	   distant	   recurrence	   is	   statistically	  significant	  (P	  =	  0.001;	  Table	  5).	  	  
Table	  5	  Binomial	  Test	  of	  Local	  versus	  Distant	  Recurrence	  	  	   Category	   N	   Observed	  Prop.	   Test	  Prop.	   P	  Group	  1	   Distant	   24	   .80	   .50	   .001	  Group	  2	   Local	   6	   .20	   	   	  Site	  of	  first	  recurrence	   Total	   	   30	   1.00	   	   	  	  Local	  recurrence	  was	  defined	  as	  recurrence	  at	  the	  site	  of	  anastomosis,	  in	  the	  stomach,	   or	   in	   the	   celiac,	   paraaortic,	   paratracheal,	   or	   mediastinal	   lymph	   nodes.	  Celiac	   nodes	   are	   the	   nodes	   located	   at	   the	   base	   of	   the	   celiac	   artery	   and	  paraaortic	  nodes	  are	   located	  lateral	  to	  the	  ligamentum	  arteriosum.	  Paratracheal	   lymph	  nodes	  are	   divided	   into	   right	   and	   left	   upper	   paratracheal	   nodes	   as	  well	   as	   right	   and	   left	  lower	  paratracheal	  nodes.	  Right	  upper	  paratracheal	  nodes	  are	  located	  between	  the	  intersection	  of	  the	  caudal	  margin	  of	  the	  innominate	  artery	  with	  trachea	  and	  the	  lung	  apex;	   left	  upper	  paratracheal	  nodes	  are	   located	  between	  the	  top	  of	   the	  aortic	  arch	  and	   the	   lung	   apex.	   Right	   lower	   paratracheal	   nodes	   are	   located	   between	   the	  intersection	   of	   the	   caudal	   margin	   of	   the	   innominate	   artery	   with	   the	   trachea	   and	  cephalic	   border	   of	   the	   azygous	   vein;	   left	   lower	   paratracheal	   nodes	   are	   located	  between	   the	   top	  of	   the	   aortic	   arch	   and	   the	   carina.	   	  Mediastinal	   nodes	   are	  divided	  
	   25	  
into	   anterior	   mediastinal	   nodes,	   located	   anterior	   to	   the	   ascending	   aorta	   or	   the	  innominate	   artery,	   and	   posterior	   mediastinal	   nodes,	   located	   above	   the	   tracheal	  bifurcation	  ("Esophagus	  and	  Esophagogastric	  Junction,"	  2009).	   	  Distant	  recurrence	  was	  defined	  as	   any	   site	  distant	   from	   the	   location	  of	   the	  original	   tumor.	  The	   lungs	  and	  liver	  combined	  were	  the	  most	  common	  sites	  of	  first	  recurrence	  in	  this	  group	  of	  patients,	  accounting	  for	  51%	  of	  cases	  (Figure	  1).	  The	  central	  nervous	  system	  (CNS),	  including	   the	   brain	   and	   leptomeninges,	   was	   the	   site	   of	   first	   recurrence	   in	   8%	   of	  cases.	  The	  bones	  and	  abdominal	  wall	  were	  each	  the	  site	  of	  first	  recurrence	  6%	  of	  the	  time.	  The	  small	  bowel,	  omentum,	  and	  serosa	  were	  the	  sites	  of	  first	  recurrence	  in	  5%	  of	  cases,	  while	  the	  adrenal	  accounted	  for	  only	  3%.	  The	  stomach,	  anastomosis,	  celiac	  nodes,	   paraaortic	   lymph	   nodes,	   and	   paratracheal	   nodes	   combined	   accounted	   for	  15%	   of	   the	   sites	   of	   first	   recurrence	   (Figure	   1).	   However,	   the	   mediastinal	   lymph	  nodes	  were	   the	   site	   of	   first	   recurrence	   in	   only	   6%	  of	   cases.	   The	   Fisher	   exact	   test	  revealed	  a	  statistically	  significant	  relationship	  between	  the	  site	  of	  first	  recurrence	  of	  esophageal	  carcinoma	  and	  tumor	  histology	  (P	  =	  0.034;	  Table	  6).	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Figure	  1	  Patterns	  of	  First	  Recurrence	  of	  Esophageal	  Cancer	  
	  
Table	  6	  Site	  of	  First	  Recurrence	  based	  on	  tumor	  histology	  








3%	   3%	   3%	   3%	   Lungs	  and	  pleura	  Liver	  CNS:	  brain,	  leptomeninges	  small	  bowel/omentum/serosa	  Bone	  Mediastinal	  lymph	  nodes	  Abdominal	  wall	  Anastomosis	  Celiac	  lymph	  nodes	  Paraaortic	  lymph	  nodes	  Paratracheal	  nodes	  Adrenal	  Stomach	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each,	  the	  CNS	  was	  involved	  in	  10%	  of	  cases,	  and	  the	  gluteal	  muscles,	  chest	  wall,	  and	  omentum	  were	  each	  involved	  in	  5%	  of	  these	  cases,	  respectively.	  	  
	  





5%	   5%	  
5%	  
Lung	  Local	  Bone	  Liver	  CNS:	  brain,	  nerve	  roots	  Gluteal	  muscles	  Chest	  wall	  Omentum	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recurrence	   (HR	  =	   0.202,	  P	   =	   0.025;	   Table	   7),	   and	   a	   significant	   increase	   in	   time	   to	  recurrence	  with	  radiation	  dose	  of	  52	  Gy	  to	  60	  Gy	  (HR	  =	  8.880,	  P	  =	  0.029;	  Table	  7).	  The	  multivariable	  analysis	  for	  time	  to	  recurrence	  also	  revealed	  that	  pathologic	  stage	  III	   disease	   is	   significantly	   associated	   with	   a	   poorer	   disease-­‐free	   survival	   (HR	   =	  4.200,	  P	  =	  0.044;	  Table	  7).	  	  	  
Table	  7	  Multivariable	  Cox	  Regression	  Analysis	  for	  Time	  to	  Recurrence	  
Characteristic	   No.	  (std	  dev)	   HR	   95%	  CI	   P	  
Histology	   	  	   	  	   	  	   	  	  Adenocarcinoma	   54	   1	   	  	   	  	  Squamous	  Cell	  Carcinoma	   7	   2.189	   0.204-­‐23.485	   0.518	  
Clinical	  Stage	   	  	   	  	   	  	   	  	  Stage	  I	   5	   1	   	  	   	  	  Stage	  II	   32	   0.081	   0.005-­‐1.368	   0.081	  Stage	  III	   24	   0.243	   0.017-­‐3.527	   0.300	  
Pathologic	  Stage	   	  	   	  	   	  	   	  	  Stage	  0	   18	   1	   	  	   	  	  Stage	  I	   10	   0.508	   0.053-­‐4.885	   0.558	  Stage	  II	   17	   0.673	   0.180-­‐2.512	   0.555	  Stage	  III	   13	   4.200	   1.043-­‐16.920	   0.044	  Stage	  IV	   3	   0.147	   0.013-­‐1.661	   0.121	  
Dose	  of	  external	  beam	  radiation	   	  	   	  	   	  	   	  	  45	  Gy	   42	   1	   	  	   	  	  50	  Gy	   15	   0.202	   0.050-­‐0.816	   0.025	  52	  Gy	  -­‐	  60	  Gy	   4	   8.880	   1.248-­‐63.183	   0.029	  	  	   Kaplan-­‐Meier	   analysis	   also	   revealed	   that	   disease-­‐free	   survival	   was	  significantly	   associated	   with	   the	   pathologic	   stage	   of	   the	   patient’s	   tumors	   after	  chemoradiotherapy	  (P	  =	  0.034;	  Figure	  4).	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Figure	  1	  Kaplan-­Meier	  Analysis	  showing	  the	  difference	  in	  disease	  free	  survival	  according	  to	  pathological	  
stage	  
Kaplan-­‐Meier	  analysis	  of	  disease-­‐free	  survival	  according	  to	  the	  dose	  of	  neoadjuvant	  radiotherapy	  patients	  received	  also	  showed	  a	  significant	  difference	  in	  disease-­‐free	  survival,	  with	  patients	  receiving	  50	  Gy	  having	  a	  longer	  disease-­‐free	  period	  than	  patients	  receiving	  45	  Gy	  or	  52	  Gy	  to	  60	  Gy	  (P	  =	  0.002;	  Figure	  5).	  The	  5-­‐year	  disease-­‐free	  survival	  was	  61.6%.	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Figure	  2	  Kaplan-­Meier	  Analysis	  showing	  the	  difference	  in	  disease-­free	  survival	  according	  to	  dose	  of	  
radiation	  therapy	  administered	  
Overall	  Survival	  There	  were	  no	  significant	  factors	  in	  the	  univariable	  analysis	  for	  overall	  survival	  (Table	  8).	  Likewise,	  in	  the	  multivariable	  analysis,	  there	  were	  no	  factors	  emerged	  as	  significantly	  influencing	  the	  overall	  survival	  (Table	  9).	  The	  5-­‐year	  overall	  survival	  was	  60.3%.	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Table	  8	  Univariable	  analysis	  for	  overall	  survival	  
Characteristic	   No.	  (std	  dev)	   HR	   95%	  CI	   P	  
Gender	   	  	   	  	   	  	   	  	  Male	   63	   1	   	  	   	  	  Female	   10	   0.697	   0.212-­‐0.295	   0.553	  Age	   58.63	   1.016	   0.976-­‐1.058	   0.439	  
Race	   	  	   	  	   	  	   	  	  Non-­‐Hispanic	  White	   64	   1	   	  	   	  	  Non-­‐Hispanic	  Black	   6	   0.518	   0.121-­‐2.230	   0.378	  Other	   3	   0.849	   0.115-­‐6.258	   0.872	  
Alcohol	  use	  history	   	  	   	  	   	  	   	  	  No	   25	   1	   	  	   	  	  Yes	   47	   0.514	   0.253-­‐1.047	   0.067	  
Tobacco	  Use	  history	   	  	   	  	   	  	   	  	  No	   9	   1	   	  	   	  	  Yes	   63	   3.910	   0.533-­‐28.690	   0.180	  
Histology	   	  	   	  	   	  	   	  	  Adenocarcinoma	   64	   1	   	  	   	  	  Squamous	  Cell	  Carcinoma	   9	   2.155	   0.877-­‐5.299	   0.094	  
Clinical	  Stage	   	  	   	  	   	  	   	  	  Stage	  I	   5	   1	   	  	   	  	  Stage	  II	   36	   0.474	   0.105-­‐2.137	   0.331	  Stage	  III	   27	   0.807	   0.182-­‐3.585	   0.778	  Stage	  IV	   1	   1.545	   0.139-­‐17.183	   0.723	  
Pathologic	  Stage	  	   	  	   	  	   	  	   	  	  Stage	  0	   20	   1	   	  	   	  	  Stage	  I	   12	   0.262	   0.031-­‐2.189	   0.217	  Stage	  II	   23	   2.246	   0.854-­‐5.911	   0.101	  Stage	  III	   14	   2.351	   0.811-­‐6.811	   0.115	  Stage	  IV	   3	   2.102	   0.418-­‐10.567	   0.367	  
Response	  to	  treatment	   	  	   	  	   	  	   	  	  No	  response	   17	   1	   	  	   	  	  Downstaging	  without	  complete	  response	   20	   0.717	   0.283-­‐1.818	   0.484	  Downstaging	  with	  complete	  response	   20	   0.481	   0.173-­‐1.334	   0.160	  Disease	  progression	   12	   0.838	   0.304-­‐2.310	   0.732	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Type	  of	  Neoadjuvant	  chemotherapy	  received	   	  	   	  	   	  	   	  	  Cisplatin/5-­‐FU	   39	   1	   	  	   	  	  Cisplatin/5-­‐FU/Taxol	   9	   0.436	   0.130-­‐1.461	   0.178	  Cisplatin/Taxol	   6	   0.235	   0.031-­‐1.753	   0.158	  Other	   15	   0.528	   0.199-­‐1.399	   0.199	  
Dose	  of	  external	  beam	  radiation	   	  	   	  	   	  	   	  	  45	  Gy	   43	   1	   	  	   	  	  50	  Gy	   17	   0.457	   0.157-­‐1.331	   0.151	  52	  Gy	  -­‐	  60	  Gy	   4	   0.969	   0.228-­‐4.124	   0.966	  	  
Table	  9	  Multivariable	  analysis	  for	  overall	  survival	  
Characteristic	   No.	   HR	   95%	  CI	   P	  
Alcohol	  use	  history	   	  	   	  	   	  	   	  	  No	   21	   1	   	  	   	  	  Yes	   39	   0.547	   0.214-­‐1.395	   0.207	  
Tobacco	  Use	  history	   	  	   	  	   	  	   	  	  No	   8	   1	   	  	   	  	  Yes	   52	   3.499	   0.415-­‐29.472	   0.249	  
Histology	   	  	   	  	   	  	   	  	  Adenocarcinoma	   54	   1	   	  	   	  	  Squamous	  Cell	  Carcinoma	   6	   1.466	   0.375-­‐5.730	   0.583	  
Pathologic	  Stage	   	  	   	  	   	  	   	  	  Stage	  0	   17	   1	   	  	   	  	  Stage	  I	   10	   0.281	   0.027-­‐2.929	   0.289	  Stage	  II	   18	   2.024	   0.524-­‐7.812	   0.306	  Stage	  III	   12	   1.570	   0.398-­‐6.198	   0.520	  Stage	  IV	   3	   5.164	   0.624-­‐42.734	   0.128	  
Type	  of	  Neoadjuvant	  chemotherapy	  received	   	  	   	  	   	  	   	  	  Cisplatin/5-­‐FU	   36	   1	   	  	   	  	  Cisplatin/5-­‐FU/Taxol	   7	   0.763	   0.171-­‐3.403	   0.723	  Cisplatin/Taxol	   5	   0	   0-­‐-­‐	   0.983	  Other	   12	   0.595	   0.199-­‐1.781	   0.353	  
Dose	  of	  external	  beam	  radiation	   	  	   	  	   	  	   	  	  45	  Gy	   42	   1	   	  	   	  	  50	  Gy	   14	   0.477	   0.144-­‐1.579	   0.226	  52	  Gy	  -­‐	  60	  Gy	   4	   0.762	   0.107-­‐5.442	   0.786	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Discussion	  In	   this	   study,	  we	   investigated	  a	   group	  of	  73	  patients	  diagnosed	  with	  either	  adenocarcinoma	   or	   squamous	   cell	   carcinoma	   of	   the	   distal	   esophagus,	  gastroesophageal	   junction,	   or	   the	  gastric	   cardia.	  All	   patients	   received	  neoadjuvant	  chemoradiotherapy	   before	   undergoing	   a	   transhiatal	   esophagectomy	  with	  minimal	  mediastinal	   lymph	   node	   dissection.	   We	   hypothesized	   that	   aggressive	   mediastinal	  control	   at	   the	   time	   of	   surgery	   may	   be	   obviated	   by	   the	   use	   of	   neoadjuvant	  chemoradiotherapy.	  Although	   the	   transthoracic	   esophagectomy	   has	   been	   associated	   with	  improved	  disease-­‐free	  and	  overall	  survival	  compared	  to	  the	  transhiatal	  approach,	  it	  is	  also	  associated	  with	  greater	  perioperative	  morbidity	  partly	  due	  to	  the	  extensive	  lymph	  node	  dissection	  involved	  (Altorki,	  et	  al.,	  2008;	  Hulscher,	  et	  al.,	  2002;	  Lee,	  et	  al.,	   2009;	  Maruyama,	   et	   al.,	   2009;	   Peyre,	   et	   al.,	   2008;	   Schipper,	   2009;	   Stiles,	   et	   al.,	  2009).	   Having	   neoadjuvant	   chemoradiotherapy	   before	   transhiatal	   esophagectomy	  has	  been	  shown	  to	  improve	  overall	  survival	  and	  patients	  also	  have	  a	  lower	  overall	  morbidity	   compared	   to	   their	   counterparts	   who	   have	   the	   more	   extensive	   surgery	  without	   neoadjuvant	   therapy	   (Gebski,	   et	   al.,	   2007;	   R.	   A.	   Malthaner,	   et	   al.,	   2006;	  Meguid,	   et	   al.,	   2009).	   	   It	   is	   therefore	   conceivable	   that	   improving	   neoadjuvant	  therapy	  at	  the	  time	  of	  transhiatal	  esophagectomy	  may	  further	  improve	  disease-­‐free	  survival	  and	  overall	  survival	  without	  increasing	  moribidity.	  Thirty	   patients	   in	   this	   study	   had	   recurrence	   of	   disease	   after	   trimodality	  therapy.	  The	  data	   further	   showed	   that	   in	   carcinomas	  of	   the	  distal	   esophagus,	  GEJ,	  and	   gastric	   cardia,	   distant	   recurrence	   is	   significantly	   more	   common	   than	   local	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recurrence	   after	   trimodality	   therapy,	   regardless	   of	   tumor	   histology.	   Given	   the	  sample	   size	  of	  30	   recurrence	  events,	   in	  a	  post-­‐hoc	  power	  calculation	   in	  which	   the	  power	   is	   set	   to	   80%,	   and	   at	   a	   0.05	   significance	   level,	   compared	   to	   the	   null	  proportion	   of	   0.5	   (representing	   equal	   proportions	   of	   both	   local	   recurrences	   and	  distant	  recurrences),	  the	  minimum	  change	  detectable	  in	  either	  group	  is	  0.21.	   	  This	  corresponds	   to	   a	  proportion	  of	  0.71	   in	  one	  group	  and	  0.29	   in	   the	  other,	   that	   is,	   9	  recurrences	  in	  one	  group	  and	  21	  in	  the	  other	  group.	  In	  this	  study,	  the	  differences	  in	  proportion	  of	  each	  group	  were	  0.80	  in	  the	  distant	  recurrence	  group,	  and	  0.20	  in	  the	  local	   recurrence	   group,	   both	   of	   which	   are	   greater	   than	   the	   minimum	   difference	  required	  for	  80%	  power.	  It	  has	  also	  been	  shown	  previously	  that	  distant	  recurrence	  is	  more	  common	  than	  local	  recurrence	  (Kleinberg,	  et	  al.,	  2003).	  The	  most	  common	  sites	  of	  first	  recurrence	  as	  well	  as	  later	  recurrence	  in	  this	  study	  were	  the	  lungs	  and	  liver,	  followed	  by	  the	  bones	  and	  the	  central	  nervous	  system.	  Since	  the	  sites	  of	  failure	  after	   transhiatal	   esophagectomy	  are	  more	   likely	   to	   be	  distant	   from	   the	   site	   of	   the	  primary	   tumor	   than	   in	   the	   mediastinal	   lymph	   nodes	   or	   even	   locally	   at	   the	  anastomosis,	  this	  obviates	  the	  need	  for	  extensive	  mediastinal	  lymph	  node	  dissection	  at	   the	   time	   of	   surgery	   and	   suggests	   the	   need	   for	   improved	   systemic	   therapy.	  Although	   other	   studies	   have	   shown	   a	   trend	   toward	   improved	   disease-­‐free	   and	  overall	   survival	   with	   chemotherapy,	   in	   the	   current	   study,	   the	   neoadjuvant	  chemotherapy	  regimen	  did	  not	  significantly	  impact	  disease-­‐free	  survival	  (Kleinberg,	  et	  al.,	  2003;	  R.	  A.	  Malthaner,	  et	  al.,	  2006).	  However,	   in	  this	  retrospective	  study,	  the	  type	  of	  neoadjuvant	  chemotherapy	  as	  well	  as	  the	  duration	  of	  administration	  was	  not	  controlled	   and	   a	   randomized	   controlled	   trial	   comparing	   standard	   chemotherapy	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regimens	  with	  regard	  to	  disease-­‐free	  survival	  in	  this	  patient	  population	  is	  needed	  to	  determine	  how	  neoadjuvant	  chemotherapy	  affects	  disease	  recurrence.	  The	  rates	  of	  failure	  were	  significantly	  associated	  with	  the	  pathologic	  stage	  of	  the	  disease	  as	  patients	  who	  had	  stage	  III	  disease	  after	  chemoradiotherapy	  tended	  to	  have	  recurrence	  earlier	  than	  their	  counterparts	  who	  had	  either	  no	  residual	  disease	  after	   therapy	   or	   those	   who	   had	   residual	   disease	   but	   stage	   lower	   than	   III.	   The	  pathological	  response	  to	  therapy	  and	  pathologic	  stage	  after	  therapy	  have	  also	  been	  shown	   to	  be	   important	  predictors	  of	   survival	   (Kleinberg,	  et	  al.,	  2003;	  Meredith,	   et	  al.).	   Only	   3	   patients	   in	   the	   study	   had	   stage	   IV	   disease	   after	   therapy	   and	  with	   this	  small	   sample	  of	  patients,	   there	  was	  no	  significant	  association	  of	  having	  pathologic	  stage	   IV	   disease	   after	   trimodality	   therapy	   and	   the	   time	   to	   recurrence.	   Although	  many	  patients	  who	  had	  residual	  disease	  in	  the	  study	  were	  treated	  adjuvantly,	  these	  regimens	  varied	  with	  the	  provider	  and	  the	  numbers	  were	  too	  small	  to	  include	  in	  the	  analysis.	  However,	  since	  sites	  of	  failure	  are	  predominantly	  distant,	  a	  goal	  for	  future	  study	  may	  be	   to	   investigate	  how	  systemic	  adjuvant	   chemotherapy	  affects	  disease-­‐free	  survival	  in	  patients	  with	  residual	  disease	  after	  trimodality	  therapy.	  Failure	  rates	  were	  reduced	  with	  a	  dose	  of	  neoadjuvant	  radiotherapy	  of	  50	  Gy	  compared	   to	   a	   dose	   of	   45	   Gy.	   The	   improvement	   in	   disease-­‐free	   survival	   with	   a	  slightly	   higher	   dose	   of	   radiation	  may	   be	   related	   to	   enhanced	   tumor	   downstaging	  leading	   to	   a	   lower	   pathological	   stage	   of	   disease,	   which	   was	   also	   shown	   to	   be	  associated	  with	   risk	   of	   disease	   recurrence.	   However,	   the	   number	   of	   patients	  who	  received	  50	  Gy	  radiation	  was	  small	  (n	  =	  17)	  compared	  to	  those	  who	  received	  45	  Gy	  (n	   =	   43)	   and	   there	  may	   be	   confounding	   factors	   such	   as	   the	   difference	   in	   disease	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burden	  before	  therapy	  that	  may	  be	  masked	  by	  this	  small	  number.	  Given	  the	  sample	  sizes	  in	  the	  45	  Gy	  and	  50	  Gy	  groups,	  a	  post-­‐hoc	  power	  calculation	  in	  which	  power	  is	  set	   to	   80%	   will	   detect	   a	   minimum	   difference	   in	   hazard	   ratio	   of	   0.5.	   	   This	  corresponds	  to	  a	  50%	  difference	  in	  risk	  of	  recurrence.	  The	  hazard	  ratio	  obtained	  in	  this	  case	  was	  0.202,	  which	  is	  a	  difference	  in	  hazard	  ratio	  of	  1.798,	  which	  is	  greater	  than	  the	  minimum	  difference	  of	  0.5.	  On	  the	  other	  hand,	  rates	  of	  failure	  appeared	  to	  increase	  with	  radiation	  dose	  between	  52	  Gy	  and	  60	  Gy	  (P	  =	  0.029)	  but	  the	  confidence	  interval	  was	  large	  (1.248-­‐63.183)	  and	  the	  result	  is	  limited	  by	  both	  the	  small	  number	  of	  patients	  (n	  =	  4)	  who	  received	   a	  dose	   in	   this	   range	   as	  well	   as	   the	  disease	  burden	  of	   the	  patients	  before	  therapy	  that	  may	  have	  influenced	  the	  decision	  to	  treat	  with	  a	  higher	  radiation	  dose.	  Given	  the	  sample	  sizes	  of	  patients	  who	  received	  45	  Gy	  and	  those	  who	  received	  52-­‐60	   Gy,	   a	   post-­‐hoc	   power	   calculation	   in	   which	   power	   is	   set	   to	   80%	   will	   detect	   a	  minimum	  difference	  in	  hazard	  ratio	  of	  1.5.	   	  This	  corresponds	  to	  a	  150%	  difference	  in	   risk	   of	   recurrence.	   The	   hazard	   ratio	   obtained	   in	   this	   case	   was	   8.880,	   which	   is	  greater	   than	   the	   minimum	   difference	   of	   1.5.	   A	   randomized	   controlled	   trial	  comparing	   different	   doses	   of	   radiation	  with	   respect	   to	   rates	   of	   recurrence	  would	  limit	   the	   confounding	   and	   determine	   how	   radiation	   doses	   above	   50	   Gy	   affect	  disease-­‐free	   survival,	   bearing	   in	   mind	   patient	   safety	   as	   the	   risk	   of	   esophagitis	  increases	  with	  radiation	  doses	  above	  40-­‐50	  Gy	  (Werner-­‐Wasik,	  Yorke,	  Deasy,	  Nam,	  &	  Marks).	  Demographic	  factors,	  lifestyle	  factors,	  as	  well	  as	  tumor	  histology	  and	  clinical	  stage	   did	   not	   significantly	   affect	   disease-­‐free	   survival.	   However,	   lifestyle	   factors	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have	   been	   implicated	   in	   previous	   studies	   (Kountourakis,	   et	   al.;	   Vaughan,	   Davis,	  Kristal,	  &	  Thomas,	   1995).	   The	   reasons	   for	   the	  difference	  may	   include	   sample	   size	  and	  differences	  in	  the	  quantification	  of	  alcohol	  of	  tobacco	  use.	  In	  the	  current	  study,	  it	  was	  not	  possible	  to	  quantify	   the	  quantity	  of	  alcohol	  a	  patient	  consumed	  daily	  as	  this	  information	  was	  not	  necessarily	  present	  in	  the	  patients’	  medical	  record.	  It	  has	  been	  shown	  previously	  that	  overall	  survival	  improves	  in	  patients	  who	  have	   a	   pathologic	   complete	   response	   after	   receiving	   neoadjuvant	  chemoradiotherapy	   (Kleinberg,	   et	   al.,	   2003;	   Slater,	   Holland,	   Faigel,	   Sheppard,	   &	  Deveney,	   2001).	   Although	   dose	   of	   neoadjuvant	   radiotherapy	   and	   pathologic	   stage	  impacted	  disease-­‐free	  survival,	  neither	   impacted	  overall	   survival.	  Furthermore,	  no	  other	   factor	  emerged	  as	  significantly	  affecting	  overall	  survival.	  This	  may	  be	  due	  to	  the	   fact	   that	   patients	   in	   the	   study	   died	   from	  multiple	   causes	   including	  metastatic	  esophageal	  carcinoma,	  perioperative	  complications,	  and	  multiple	  other	  causes.	  There	  are	  several	  limitations	  in	  this	  study:	  (1)	  small	  sample	  size,	  (2)	  lack	  of	  a	  control	  group,	  and	  (3)	  the	  retrospective	  nature	  of	  the	  study.	  The	  small	  sample	  size	  increases	   the	   probability	   that	   observations	  made	   are	   by	   chance,	   thus	   limiting	   our	  ability	   to	   find	   significant	   relationships	   that	   may	   actually	   exist.	   In	   particular,	   the	  small	   number	   of	   patients	  with	   squamous	   cell	   carcinoma	   and	   the	   small	   number	   of	  female	  patients	  makes	  observations	  about	  relationships	  of	   these	  groups	  to	  disease	  recurrence	   difficult	   to	   determine	   statistically.	   Achieving	   a	   large	   sample	   size	   is	   a	  challenge	   since	   esophageal	   carcinoma	   is	   relatively	   rare,	   so	   multicenter	   studies	  would	  be	  necessary	  to	  achieve	  a	  large	  sample	  size.	  The	  study	  did	  not	  have	  a	  control	  group	  of	  patients	  who	  did	  not	  have	  neoadjuvant	  chemoradiotherapy	  before	  surgery,	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or	   patients	   who	   had	   chemoradiotherapy	   with	   transthoracic	   esophagectomy	   thus	  direct	   comparisons	   of	   the	   impact	   of	   the	   therapy	   versus	   other	   treatment	   options	  cannot	  be	  made,	  and	  a	  prospective	  randomized	  controlled	  study	  would	  be	  useful	  for	  that	   purpose.	   Finally,	   the	   retrospective	   nature	   of	   the	   study	   limits	   the	   ability	   to	  control	   for	   confounding	   factors	   although	   it	   enables	   us	   to	   determine	   significant	  relationships.	  Since	  local	  failure	  rates	  were	  significantly	  lower	  than	  distant	  failure	  rates	  in	  this	   study,	   it	   appears	   that	   aggressive	   mediastinal	   control	   at	   the	   time	   of	  esophagectomy	  in	  patients	  with	  adenocarcinoma	  or	  squamous	  cell	  carcinoma	  of	  the	  distal	   esophagus,	   GEJ	   and/or	   gastric	   cardia,	   who	   have	   received	   neoadjuvant	  chemoradiotherapy,	  is	  unnecessary.	  Furthermore,	  since	  pathologic	  stage	  of	  disease	  is	  significantly	  associated	  with	  disease	  recurrence,	  more	  efforts	  should	  be	  made	  to	  improve	  systemic	  therapy	  prior	  to	  and/or	  after	  resection.	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